Last updated on April 2018

Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

Brief description of study

Chronic hypoparathyroidism is a life-long disease for which the chronic administration of rhPTH(1-84) is a potential treatment option. The group of subjects in the AAAE0544 core study has been taking rhPTH(1-84) for the treatment of hypoparathyroidism for up to 11 years. This study is designed to extend this experience and gain knowledge about how safe and effective rhPTH(1-84) is in patients with hypoparathyroidism over a long-term duration.

Clinical Study Identifier: NCT02910466

Contact Investigators or Research Sites near you

Start Over

Natalie Cusano, MD, MS

Columbia University Medical Center
New York, NY United States